Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease

Trial Profile

A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Laquinimod (Primary)
  • Indications Huntington's disease
  • Focus Therapeutic Use
  • Acronyms LEGATO-HD
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 23 Sep 2019 According to an Active Biotech media release, data from this study will be presented at the International congress of Parkinsons disease and Movement disorders in Nice, France, September 22 to 26, 2019.The data will be presented in three posters.
    • 08 Aug 2019 According to an Active Biotech media release, data from this study presented at the American Academy of Neurology.
    • 03 May 2019 According to an Active Biotech media release, data from this study has been selected to be presented orally by Global Coordinating Principal Investigator, Dr. Ralf Reilmann at the scientific conference "American Academy of Neurology (ON)" (Philadelphia, PA, 6th May 2019).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top